Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Drug Class Review: Targeted Immune Modulators: Final Update 3 Report [Internet].

Thaler KJ, Gartlehner G, Kien C, Van Noord MG, Thakurta S, Wines RCM, Hansen RA, McDonagh MS.

Portland (OR): Oregon Health & Science University; 2012 Mar.

2.

Drug Class Review: Targeted Immune Modulators: Final Report Update 2 [Internet].

Gartlehner G, Thieda P, Morgan LC, Thaler K, Hansen RA, Jonas B.

Portland (OR): Oregon Health & Science University; 2009 Nov.

3.

Adverse effects of biologics: a network meta-analysis and Cochrane overview.

Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008794. doi: 10.1002/14651858.CD008794.pub2. Review.

PMID:
21328309
4.

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ.

Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Review.

PMID:
25264908
5.

Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].

Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Wilkins T, Peravali V, Bangdiwala SI, Yuen A, Thieda P, Morgan LC, Crotty K, Desai R, Van Noord M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

6.

Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report [Internet].

McDonagh M, Peterson K, Carson S, Fu R, Thakurta S.

Portland (OR): Oregon Health & Science University; 2010 Jul.

7.

A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.

Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS.

Adv Ther. 2016 Apr;33(4):626-42. doi: 10.1007/s12325-016-0312-y. Epub 2016 Mar 12.

8.

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007848. doi: 10.1002/14651858.CD007848.pub2. Review.

PMID:
19821440
9.

Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.

Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA.

Arthritis Care Res (Hoboken). 2016 Aug;68(8):1078-88. doi: 10.1002/acr.22815. Review.

PMID:
26663412
10.
11.

Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report [Internet].

Donahue KE, Jonas D, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda P, Morgan LC, Crotty K, Van Noord M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

12.

Methotrexate for induction of remission in refractory Crohn's disease.

McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG.

Cochrane Database Syst Rev. 2014 Aug 6;(8):CD003459. doi: 10.1002/14651858.CD003459.pub4. Review.

PMID:
25099640
13.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

14.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

15.

Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.

Gordon M, Taylor K, Akobeng AK, Thomas AG.

Cochrane Database Syst Rev. 2014 Aug 1;(8):CD010233. doi: 10.1002/14651858.CD010233.pub2. Review.

PMID:
25081347
16.

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.

Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.

Adv Ther. 2012 Jul;29(7):620-34. doi: 10.1007/s12325-012-0035-7. Epub 2012 Jul 27.

PMID:
22843208
17.

Anti-TNF agents for paediatric psoriasis.

Sanclemente G, Murphy R, Contreras J, García H, Bonfill Cosp X.

Cochrane Database Syst Rev. 2015 Nov 24;(11):CD010017. doi: 10.1002/14651858.CD010017.pub2. Review.

PMID:
26598969
18.

Drug Class Review: Controller Medications for Asthma: Final Update 1 Report [Internet].

Jonas DE, Wines RCM, DelMonte M, Amick HR, Wilkins TM, Einerson BD, Schuler CL, Wynia BA, Shilliday BB.

Portland (OR): Oregon Health & Science University; 2011 Apr.

19.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

20.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120

Supplemental Content

Support Center